Amycretin official-source update · version 1
This page preserves this version’s findings and source pins. Open the current profile →
Official-source update
Reviewed 2026-09-19 · Preserved version 1
The injection and oral studies are separate
NCT06064006 records 125 participants in a completed study of subcutaneous NNC0487-0111. NCT06049329 records a separate 36-participant oral study in Japanese men. These populations and routes should not be pooled as one trial. NCT06064006 ↗NCT06049329 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
The registered primary questions concerned adverse events
Both records list treatment-emergent adverse events as primary outcomes, with different observation windows across study parts. A weight change reported elsewhere is not automatically the primary endpoint of either registered study. NCT06064006 ↗NCT06049329 ↗
Enrollment was selective
The subcutaneous study enrolled adults aged 18–55 within a specified BMI range and excluded diabetic-range HbA1c. The oral study was restricted to Japanese men. These designs do not establish effects across all ages, diabetes populations or demographic groups. NCT06064006 ↗NCT06049329 ↗
Completion does not supply registry results
Both retrieved records are marked completed but contain no posted summary-results section. This is a registry-specific observation as of September 19, 2026, not a claim that trial publications or other reports do not exist. NCT06064006 ↗NCT06049329 ↗
What remains to be checked
- Match oral and subcutaneous publications to exact protocols and reconcile their analysis populations.
- Review later trials and result postings without treating these selected records as a complete development inventory.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity ↗
Source dated 2025-03-05; retrieved 2026-09-19.
- protocolSection.identificationModule, designModule and armsInterventionsModule
- protocolSection.eligibilityModule and armsInterventionsModule
- protocolSection.outcomesModule
- protocolSection.statusModule; presence or absence of resultsSection in retrieved record
SHA-256:
bcedaf5fb0ab31b31f1194f4f1e878a5ef0f74262c587127a87fffc8dfe68b1fA Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin ↗
Source dated 2025-11-19; retrieved 2026-09-19.
- protocolSection.identificationModule, designModule and armsInterventionsModule
- protocolSection.eligibilityModule and armsInterventionsModule
- protocolSection.outcomesModule
- protocolSection.statusModule; presence or absence of resultsSection in retrieved record
SHA-256:
07b607555cf7f16ab5bfedbe4a491fd148e8c233c5bc46f36ba9be330e301658